Gastric Adenocarcinoma Mechanisms and Treatment Approaches

Gastric adenocarcinoma arises from the malignant transformation of gastric epithelium, driven by a confluence of environmental, microbial and molecular factors. Chronic infection with Helicobacter pylori initiates a cascade of gastritis, atrophy and intestinal metaplasia, creating a pro-tumoural niche. Genomic aberrations—such as mutations in TP53, CDH1 and GNAS—combine with epigenetic alterations and dysregulation of pathways including Wnt/β-catenin, HER2 and PI3K/Akt to promote tumour initiation and progression. Recent molecular classifications stratify disease into subtypes with distinct behaviour and therapeutic vulnerability. Early-stage lesions confined to the mucosa or superficial submucosa are amenable to endoscopic submucosal dissection, whereas more advanced disease requires subtotal or total gastrectomy with lymphadenectomy. Systemic therapy has evolved beyond conventional cytotoxics to include HER2-targeted trastuzumab, anti-angiogenic agents and PD-1 immune checkpoint inhibitors. Ongoing efforts aim to refine precision medicine through comprehensive genomic profiling, microenvironment modulation and novel combination regimens.

Research from Nature Portfolio

Recent studies have demonstrated that endoscopic resection is both safe and effective for early fundic-gland-type lesions. Analysis of over 100 oxyntic gland adenomas and gastric adenocarcinomas of fundic-gland type has shown that all were limited to mucosal or superficial submucosal layers, with negligible rates of lymphovascular invasion. Among patients who underwent endoscopic mucosal resection or submucosal dissection, vertical margins were uniformly negative and no recurrences were observed during follow-up. These findings support a paradigm shift towards minimally invasive management of well-differentiated fundic-gland tumours and underscore the importance of lesion depth assessment in guiding therapeutic choice.

Gastric Adenocarcinoma Mechanisms and Treatment Approaches publication trend

The graph below shows the total number of articles in gastric adenocarcinoma mechanisms and treatment approaches across all publications each year (not limited to Nature Index journals).

Technical terms

GNAS mutation: activating alteration in the gene encoding Gα_s protein that drives aberrant cyclic AMP signalling in fundic-gland neoplasms.

Oxyntic gland adenoma: benign proliferation of chief and parietal cells arising in the gastric fundus, often pre-malignant.

Endoscopic submucosal dissection (ESD): advanced endoscopic technique enabling en bloc removal of superficial gastrointestinal tumours.

Helicobacter pylori: gastric pathogen whose chronic colonisation induces inflammation, atrophy and promotes carcinogenesis.

Epigenotype: genome-wide DNA methylation profile that categorises tumours into low, intermediate or high methylation subgroups.

Microsatellite instability (MSI): hypermutable state from defective mismatch repair leading to insertion/deletion mutations at short tandem repeats.

References

1. Gastric epithelial neoplasm of fundic-gland mucosa lineage: proposal for a new classification in association with gastric adenocarcinoma of fundic-gland type. Journal of Gastroenterology (2021).
2. Endoscopic resection is a suitable initial treatment strategy for oxyntic gland adenoma or gastric adenocarcinoma of the fundic gland type. Scientific Reports (2021).
3. The clinicopathological and molecular features of sporadic gastric foveolar type neoplasia. Virchows Archiv (2020).
4. Endoscopic features of oxyntic gland adenoma and gastric adenocarcinoma of the fundic gland type differ between patients with and without Helicobacter pylori infection: a retrospective observational study. BMC Gastroenterology (2022).